RKT.L
Reckitt Benckiser Group plc
$5,430.00
-88.00
(-1.59%)
Mkt Cap
34.41B
Volume
2,063,832
52W Range
3664-6522.92
Sector
Consumer Defensive
Beta
0.26
EPS (TTM)
4.88 GBP
P/E Ratio
1112.70
Revenue (TTM)
14.21B GBP
Rev Growth (5Y)
+0.3%
EPS Growth (5Y)
+23.9%
Company Description
Reckitt Benckiser Group Plc engages in the manufacture and trade of consumer brand products including Air Wick, Calgon, Cillit Bang, Clearasil, Dettol, Durex, Enfamil, Finish, Gaviscon, Harpic, Lysol, Mortein, Mucinex, Nurofen, Nutramigen, Strepsils, Vanish, Veet, and Woolite. It operates through the following segments: Hygiene, Health, and Nutrition. The company was founded by Isaac Reckitt in 1840 and is headquartered in Slough, the United Kingdom.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 14.21B | 14.17B | 14.61B | 14.45B | 13.23B | 13.99B | 12.85B | 12.60B | 11.45B | 9.48B | 8.87B | 8.84B |
| Net Income | 3.18B | 1.43B | 1.64B | 2.33B | (32.00M) | 1.19B | (2.77B) | 2.16B | 3.38B | 1.83B | 1.74B | 1.66B |
| EPS | 4.88 | 2.04 | 2.29 | 3.27 | -0.04 | 1.67 | -3.91 | 3.06 | 4.81 | 2.60 | 2.44 | 2.31 |
| Free Cash Flow | 1.76B | 2.22B | 2.19B | 1.95B | 1.32B | 3.12B | 968.00M | 2.02B | 2.21B | 2.25B | 1.63B | 1.94B |
| FCF / Share | 2.70 | 3.17 | 3.05 | 2.73 | 1.85 | 4.39 | 1.37 | 2.86 | 3.14 | 3.19 | 2.29 | 2.69 |
| Operating CF | 2.30B | 2.68B | 2.64B | 2.40B | 1.70B | 3.52B | 1.41B | 2.45B | 2.49B | 2.42B | 1.78B | 2.10B |
| Total Assets | 25.07B | 25.30B | 27.14B | 28.74B | 26.95B | 31.29B | 32.14B | 37.65B | 37.01B | 18.02B | 15.27B | 15.50B |
| Total Debt | 8.43B | 8.66B | 8.54B | 8.88B | 9.56B | 10.56B | 12.20B | 11.88B | 12.86B | 2.39B | 2.42B | 2.57B |
| Cash & Equiv | 1.95B | 760.00M | 1.39B | 1.16B | 1.26B | 1.65B | 1.55B | 1.48B | 2.12B | 882.00M | 740.00M | 917.00M |
| Book Value | 7.75B | 6.70B | 8.45B | 9.44B | 7.40B | 9.12B | 9.36B | 14.74B | 13.53B | 8.42B | 6.90B | 6.83B |
| Return on Equity | 0.41 | 0.21 | 0.19 | 0.25 | -0.00 | 0.13 | -0.30 | 0.15 | 0.25 | 0.22 | 0.25 | 0.24 |
| Metric | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 | Q4 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 6.41B | 7.22B | 6.98B | 7.00B | 7.17B | 7.16B | 7.45B | 7.57B | 6.89B | 6.64B | 6.60B | 7.08B |
| Net Income | 652.00M | 2.22B | 958.00M | 284.00M | 1.14B | 402.00M | 1.23B | 991.00M | 1.35B | 1.69B | (1.73B) | 112.00M |
| EPS | 1.01 | 3.45 | 0.71 | 0.41 | 1.61 | 0.56 | 1.72 | 1.38 | 1.88 | 2.37 | -2.42 | 0.16 |
| Free Cash Flow | 440.00M | 1.11B | 327.00M | 1.46B | 856.00M | 1.44B | 746.00M | 1.29B | 662.00M | 722.00M | 525.00M | 1.14B |
| FCF / Share | 0.68 | 1.72 | 0.48 | 2.08 | 1.21 | 2.01 | 1.04 | 1.81 | 0.93 | 1.01 | 0.74 | 1.61 |
| Operating CF | 614.00M | 1.49B | 406.00M | 1.70B | 982.00M | 1.70B | 935.00M | 1.56B | 837.00M | 985.00M | 712.00M | 1.48B |
| Total Assets | 24.43B | 25.07B | 24.62B | 25.30B | 26.41B | 27.14B | 27.52B | 28.74B | 29.01B | 26.95B | 27.73B | 31.29B |
| Total Debt | 10.16B | 8.43B | 9.40B | 8.66B | 8.90B | 8.54B | 8.64B | 8.88B | 9.73B | 9.56B | 10.60B | 10.56B |
| Cash & Equiv | 878.00M | 1.95B | 963.00M | 760.00M | 986.00M | 1.39B | 1.03B | 1.16B | 1.29B | 1.26B | 1.48B | 1.65B |
| Book Value | 5.67B | 7.75B | 6.31B | 6.70B | 8.07B | 8.45B | 9.19B | 9.44B | 8.93B | 7.40B | 6.55B | 9.12B |
| Return on Equity | 0.11 | 0.29 | 0.15 | 0.04 | 0.14 | 0.05 | 0.13 | 0.10 | 0.15 | 0.23 | -0.26 | 0.01 |
RKT.L News
